Crown Bioscience, Inc. (Taicang)
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
0
Ending by 2030
Jun 2033
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Apr 15, 2027The maintenance fee for Use of Egfr Biomarkers for the Treatment of Gastric Cancer with Anti-Egfr Agents (US 10,442,862) comes due Apr 15, 2027. Unpaid by Oct 15, 2027, it lapses early.
- 1 fee due Jun 10, 2027The maintenance fee for Methods for determining responsiveness to MEK/ERK inhibitors (US 10,501,805) comes due Jun 10, 2027. Unpaid by Dec 10, 2027, it lapses early.
- 1 fee due Oct 14, 2027The maintenance fee for Anti-CTLA4 antibodies (US 10,618,962) comes due Oct 14, 2027. Unpaid by Apr 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 10 of 10
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,359,338 | Cyclopropanecarboxamido-substitute aromatic compounds as anti-tumor agents In force · From the USPTO record | In force | From the USPTO record | |
| US 11,136,625 | Gene expression signatures predictive of subject response to a multi-kinase inhibitor and methods of using the same In force · From the USPTO record | In force | From the USPTO record | |
| US 10,442,862 | Use of Egfr Biomarkers for the Treatment of Gastric Cancer with Anti-Egfr Agents In force · High confidence | In force | High confidence | |
| US 9,743,646 | Method of establishing isogenic multi-xenograft model and the use thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 10,501,805 | Methods for determining responsiveness to MEK/ERK inhibitors In force · From the USPTO record | In force | From the USPTO record | |
| US 10,683,550 | HNF4G-RSPO2 fusion gene and use thereof in treatment of cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 10,618,962 | Anti-CTLA4 antibodies In force · From the USPTO record | In force | From the USPTO record | |
| US 11,640,849 | Methods for Histological Diagnosis and Treatment of Diseases In force · High confidence | In force | High confidence | |
| US 11,459,618 | System and method for determining Cetuximab sensitivity on gastric cancer In force · From the USPTO record | In force | From the USPTO record | |
| US 11,339,447 | System and method for determining Kareniticin sensitivity on cancer In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 10: 2 patents in force now held by others · 1 lapsed for an unpaid fee. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 no status recorded